JP2012244993A5 - - Google Patents

Download PDF

Info

Publication number
JP2012244993A5
JP2012244993A5 JP2012119327A JP2012119327A JP2012244993A5 JP 2012244993 A5 JP2012244993 A5 JP 2012244993A5 JP 2012119327 A JP2012119327 A JP 2012119327A JP 2012119327 A JP2012119327 A JP 2012119327A JP 2012244993 A5 JP2012244993 A5 JP 2012244993A5
Authority
JP
Japan
Prior art keywords
composition
daclizumab
dac hyp
administered
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012119327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012244993A (ja
JP6055615B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012244993A publication Critical patent/JP2012244993A/ja
Publication of JP2012244993A5 publication Critical patent/JP2012244993A5/ja
Application granted granted Critical
Publication of JP6055615B2 publication Critical patent/JP6055615B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012119327A 2011-05-27 2012-05-25 Ｄａｃｈｙｐ組成物および方法 Expired - Fee Related JP6055615B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27
US61/490,998 2011-05-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016161679A Division JP2016210796A (ja) 2011-05-27 2016-08-22 Ｄａｃ ｈｙｐ組成物および方法

Publications (3)

Publication Number Publication Date
JP2012244993A JP2012244993A (ja) 2012-12-13
JP2012244993A5 true JP2012244993A5 (enExample) 2015-04-09
JP6055615B2 JP6055615B2 (ja) 2016-12-27

Family

ID=46177353

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012119327A Expired - Fee Related JP6055615B2 (ja) 2011-05-27 2012-05-25 Ｄａｃｈｙｐ組成物および方法
JP2016161679A Pending JP2016210796A (ja) 2011-05-27 2016-08-22 Ｄａｃ ｈｙｐ組成物および方法
JP2018073025A Pending JP2018134091A (ja) 2011-05-27 2018-04-05 Ｄａｃ ｈｙｐ組成物および方法
JP2020034673A Withdrawn JP2020078348A (ja) 2011-05-27 2020-03-02 Ｄａｃ ｈｙｐ組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016161679A Pending JP2016210796A (ja) 2011-05-27 2016-08-22 Ｄａｃ ｈｙｐ組成物および方法
JP2018073025A Pending JP2018134091A (ja) 2011-05-27 2018-04-05 Ｄａｃ ｈｙｐ組成物および方法
JP2020034673A Withdrawn JP2020078348A (ja) 2011-05-27 2020-03-02 Ｄａｃ ｈｙｐ組成物および方法

Country Status (10)

Country Link
US (7) US20120301429A1 (enExample)
EP (1) EP2527429A3 (enExample)
JP (4) JP6055615B2 (enExample)
CN (2) CN107090040A (enExample)
AU (4) AU2012203095B2 (enExample)
BR (1) BR102012012673A8 (enExample)
CA (1) CA2777978A1 (enExample)
MX (1) MX339533B (enExample)
RU (2) RU2661764C2 (enExample)
SG (1) SG185920A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2661764C2 (ru) * 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Композиции и способы на основе dac hyp
EP2741773A1 (en) * 2011-08-08 2014-06-18 AbbVie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis
CA2857298A1 (en) * 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG11201510788XA (en) 2013-09-04 2016-01-28 Emd Millipore Corp Protein a chromatography
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
ES2936088T3 (es) * 2015-03-23 2023-03-14 Alexion Pharma Inc Filtración de virus
CA2938333A1 (en) 2015-08-12 2017-02-12 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
CA3233933A1 (en) * 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Compositions and methods for reducing bioburden in chromatography
AU2018392697B2 (en) * 2017-12-21 2025-08-14 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
EP3956046A1 (en) * 2019-04-17 2022-02-23 Bristol-Myers Squibb Company Methods for regenerating chromatography resins
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
US12649764B2 (en) * 2019-08-01 2026-06-09 Regeneron Pharmaceuticals, Inc. Method for viral inactivation
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
RU2318537C2 (ru) * 2001-04-06 2008-03-10 Юниверсити Оф Бристоль Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CA2655246A1 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
EP2069387A4 (en) * 2006-06-14 2011-02-02 Glaxosmithkline Llc METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC
WO2008004931A1 (en) * 2006-07-06 2008-01-10 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
CA2717614A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
BRPI0918842A2 (pt) * 2008-08-28 2015-12-08 Abbott Biotherapeutics Corp método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
US20120329709A1 (en) * 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US8536316B2 (en) * 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
RU2661764C2 (ru) * 2011-05-27 2018-07-19 Эббви Байотекнолоджи Лтд., Композиции и способы на основе dac hyp

Similar Documents

Publication Publication Date Title
RU2018119112A (ru) Композиции и способы на основе dac hyp
EP2964674B1 (en) Anti-tnf-anti-il-17 bispecific antibodies
TW516962B (en) A human TNFR1-IgG1 preparation
EP3063174B1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
US20080167450A1 (en) Methods of purifying proteins
KR20120100914A (ko) 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료
AU2017206006B2 (en) Modulation of afucosylated species in a monoclonal antibody composition
JP6514789B2 (ja) 新規組換え抗ＴＮＦ−αキメラモノクローナル抗体の製造方法及び用途
EP2844290A1 (en) Novel antibodies
EP3101035A1 (en) Bifunctional fusion protein, preparation method therefor, and use thereof
US20190048070A1 (en) Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
CN107208081B (zh) 用于从包含污染宿主细胞蛋白质的材料纯化重组人α-半乳糖苷酶A的方法
WO2017038986A1 (ja) 組換えタンパク質の製造方法
TWI891671B (zh) 血清白蛋白與生長激素之融合蛋白質之製造方法
HK40091815A (en) Recombinant antibody having unique glycan profile produced by cho host cell with edited genome and preparation method thereof
HK40091814A (en) Recombinant antibody having unique glycan profile produced by cho host cell with edited genome and preparation method thereof
HK1241916A1 (en) Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins